DeepMed Research

NEW YORK MEDICAL COLLEGE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1860-01-01

Employees: 501

Market Cap: -

Website: http://www.nymc.edu

Clinical Trials

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Phase 2

Recruiting

Conditions: Non-Hodgkin Lymphoma
Burkitt Lymphoma
Diffuse Large B-Cell Lymphoma
Primary Mediastinal B-cell Lymphoma
CD20+ Lymphoblastic Lymphoma
Follicular Lymphoma, Grade III

Interventions: Drug: Obinutuzumab
Drug: Liposomal ARA-C
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2015-03-19

Last Posted Date: 2023-10-26

Lead Sponsor: New York Medical College

Target Recruit Count: 25

Registration Number: NCT02393157

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States

Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry

Recruiting

Conditions: Pulmonary Vascular Disease
Pulmonary Arterial Hypertension

First Posted Date: 2014-09-26

Last Posted Date: 2025-03-13

Lead Sponsor: New York Medical College

Target Recruit Count: 2500

Registration Number: NCT02249923

Locations: 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸
University California San Francisco, San Francisco, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 11 locations

Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

Phase 2

Completed

Conditions: Myelodysplastic Syndrome
Acute Myelogenous Leukemia

Interventions: Drug: Gemtuzumab Ozogamicin

First Posted Date: 2014-08-20

Last Posted Date: 2023-10-26

Lead Sponsor: New York Medical College

Target Recruit Count: 25

Registration Number: NCT02221310

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States

ODSH + ICE Chemotherapy in Pediatric Solid Tumors

Phase 1

Terminated

Conditions: Refractory Solid Tumor
Sarcoma
Recurrent Solid Tumor
Wilms' Tumor
Neuroblastoma

Interventions: Drug: ODSH

First Posted Date: 2014-06-16

Last Posted Date: 2017-12-22

Lead Sponsor: New York Medical College

Target Recruit Count: 4

Registration Number: NCT02164097

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States

SCT Plus Immune Therapy in Average Risk AML/MDS

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Gemtuzumab Ozogamicin

First Posted Date: 2014-04-17

Last Posted Date: 2023-10-26

Lead Sponsor: New York Medical College

Target Recruit Count: 26

Registration Number: NCT02117297

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States

Study of Thyroid Hormones in Prematures

Phase 3

Withdrawn

Conditions: Transient Hypothyroxinemia of Prematurity (THOP)

Interventions: Drug: thryoid hormone T4 + oral potassium iodide (KI) for 42 days
Drug: D5W - 5% dextrose water

First Posted Date: 2014-04-04

Last Posted Date: 2019-04-24

Lead Sponsor: New York Medical College

Registration Number: NCT02103998

Locations: 🇺🇸
Maria Fareri Childrens Hospital, Valhalla, New York, United States

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Phase 1

Active, not recruiting

Conditions: Hodgkin Lymphoma

Interventions: Drug: Brentuximab Vedotin
Procedure: Allogeneic Stem Cell Transplantation
Drug: Reduced Intensity Conditioning

First Posted Date: 2014-03-28

Last Posted Date: 2022-10-27

Lead Sponsor: New York Medical College

Target Recruit Count: 20

Registration Number: NCT02098512

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States

3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma

Phase 1

Completed

Conditions: Non-Hodgkins Lymphoma
Hodgkins Lymphoma
Lymphoproliferative Disorder

Interventions: Drug: EBV CTL's
Other: Peripheral Blood Donor

First Posted Date: 2014-02-07

Last Posted Date: 2017-12-22

Lead Sponsor: New York Medical College

Target Recruit Count: 1

Registration Number: NCT02057445

Locations: 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
New York Medical College, Valhalla, New York, United States

Treatment for Advanced B-Cell Lymphoma

Phase 2

Completed

Conditions: Diffuse Large Cell Lymphoma
High Grade B-cell Lymphoma
Burkitt's Lymphoma

Interventions: Drug: Rituximab
Drug: IT Cytarabine

First Posted Date: 2013-05-22

Last Posted Date: 2022-10-25

Lead Sponsor: New York Medical College

Target Recruit Count: 45

Registration Number: NCT01859819

Locations: 🇺🇸
Levine Children's Hospital, Charlotte, North Carolina, United States
🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

and more 2 locations

Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia

Phase 1

Completed

Conditions: Burkitt Lymphoma/Leukemia
Acute Lymphoblastic Leukemia
Acute Myelogenous Leukemia
Lymphoblastic Lymphoma
Diffuse Large B-cell Lymphoma

Interventions: Drug: Clofarabine
Drug: Mitoxantrone

First Posted Date: 2013-04-30

Last Posted Date: 2022-10-25

Lead Sponsor: New York Medical College

Target Recruit Count: 41

Registration Number: NCT01842672

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸
Levine Children's Hospital, Charlotte, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy